• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 13, 2019

View Archived Issues

Esketamine dream maybe not uphill drill; FDA panel favorable to J&J TRD bid

Trouble surfaced early in the joint FDA panel meeting to deliberate the drug-device combo esketamine 28-mg single-use nasal spray from Johnson & Johnson unit Janssen Pharmaceuticals Inc. when an agency official said U.S. gatekeepers didn't necessarily agree about the efficacy offered to support the ketamine-derived therapy for treatment-resistant depression (TRD). Read More

South Korea's SK edges closer to first independent FDA approval

With a new drug application (NDA) filed at the FDA, SK Life Science Inc., part of one of South Korea's largest conglomerates, is taking a big step closer to gaining a foothold in the U.S. epilepsy treatment market. Now awaiting a Nov. 21 PDUFA date, the company's candidate cenobamate is poised to become its first-ever independent biopharma success in America. A commercial launch for the medicine, which would be initially marketed as an adjunctive therapy, could arrive as early as the first quarter of 2020. An approval would be followed by a 90-day DEA review for scheduling. Read More

Consensus is building on taking action to bring down Rx drug prices

While there was not much new among the solutions offered at a U.S. House committee hearing Tuesday on how to rein in prescription drug prices in the U.S., what was apparent is that a consensus toward action is growing between lawmakers regardless of political party and among the policy experts who bring varying perspectives on the problem. Read More

'Stupid idea'; panelists deride proposed IPI model as disastrous for biopharma

NEW YORK – As the U.S. House Ways and Means Committee was hearing testimony from a handful of experts Tuesday morning on how to tackle the rising cost of drug prices, a few hundred miles away panelists at the BIO CEO & Investor Conference also were discussing the need to cut patients' out-of-pocket expenses. Addressing a roomful of biopharma execs and investors in the New York Marriott Marquis in Times Square, the panel members all agreed that the Trump administration's proposed International Pricing Index (IPI) payment model, aimed at reducing reimbursement levels for the Centers for Medicare & Medicaid Services, is not the way to do it. Read More

Neurogene raises $68.5M series A for AAV-based therapies

Neurogene Inc., a New York-based company developing a pipeline of gene therapies for rare neurological diseases, has secured a $68.5 million series A financing to support its work. Investors in the adeno-associated virus (AAV)-focused startup included Samsara Biocapital, EcoR1 Capital, Cormorant Asset Management, Redmile Group and an undisclosed healthcare investment fund. Read More

Other news to note

Boehringer Ingelheim (Canada) Ltd., of Burlington, Ontario, and IBM Canada, of Markham, Ontario, said they plan to explore the use of blockchain technology in clinical trials, which they said marks the first application of the technology in a trial setting in Canada. Details of the transaction and alliance were not disclosed. Read More

Financings

Ico Therapeutics Inc., of Vancouver, British Columbia, said it issued 4 million units, priced at CA5 cents to a Canadian institutional investor in a non-brokered private placement. The total gross proceeds were CA$200,000 (US$150,896). Each unit consists of one common share and one common share purchase warrant exercisable at CA$0.075 for 36 months from the date of the closing of the private placement. Read More

Clinical data for Feb. 12, 2019

Read More

Regulatory actions for Feb. 12, 2019

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe